Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
You may also be interested in...
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On
US agency has received 'very few' inquiries about the drugs on the list since its release.
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.